Popular on EntSun
- Still Using Ice? FrostSkin Reinvents Hydration - 188
- Ice Melts. Infrastructure Fails. What Happens to Clean Water? - 173
- Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy - 161
- From Boardroom to Broadcast: Vegas Circle Podcast Goes Live in Las Vegas - 154
- Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments - 150
- François Arnaud, star of Heated Rivalry, is the real-life inspiration behind Christopher Stoddard's novel At Night Only - 148
- Author, Philanthropist Ethel Gardner Joins Creators' Rights Movement Advisory Board - 145
- Cold. Clean. Anywhere. Meet FrostSkin - 142
- From "Law & Order" to the Lens: Matthew Bennett Photography Redefines the Professional Portrait in Downtown Toronto - 141
- HBMHCW Expande Infraestructura de Cumplimiento para Argentina mientras América Latina Supera $1.5 Billones en Volumen Cripto - 135
Similar on EntSun
- Dr. Sheel Desai Solomon and Preston Dermatology Continue Awards Streak with Top Honors in 2026 Maggy Awards
- $167 Billion Pharma R&D Market Largely Untapped by AI Creates Major Growth Runway for KALA Bios Data-Sovereign AI Strategy: N A S D A Q: KALA
- Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
- National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP
- Tarrytown Expocare Pharmacy Announces Strategic Leadership Appointments to Accelerate Growth and Innovation
- NaturismRE Launches the NRE Health Institute to Advance Evidence-Informed Public Health Research
- Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
- CCHR: While Damaging Antipsychotics Win Approval, Proven Non-Drug Alternatives Remain Ignored
- At 25, She Became One of the Youngest AAPI Female Founders to Win One of the World's Most Prestigious Design Awards for a Lamp That Makes You Smile
- Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX
NETRF Awards Ten Groundbreaking Research Grants to Advance Neuroendocrine Cancer Treatment
EntSun News/11049288
BOSTON - EntSun -- The Neuroendocrine Tumor Research Foundation (NETRF) today announced its newest neuroendocrine cancer research grant recipients. The ten investigators receiving awards are studying the most promising scientific approaches to
understanding and treating neuroendocrine cancer. Funding for these ten grants totals $2
million, bringing NETRF's all-time investment in research to $39.8 million.
"As the largest global funder of neuroendocrine cancer research, NETRF is the lifeline for
dedicated scientists working tirelessly to unravel the complexities of this uncommon and
challenging disease," said Elyse Gellerman, NETRF's chief executive officer. "NETRF is making the impossible, possible by accelerating leading-edge research in early detection and
personalized treatments. With this crucial funding, we're not just advancing science—we're
paving the way to a future without neuroendocrine cancer," she said.
The new awardees will focus on these themes in neuroendocrine cancer research:
More on EntSun News
● Discovering the origins of neuroendocrine cancer and causes of disease progression
● Investigating new molecular targets for treatment
● Identifying novel approaches to combat drug resistance to existing treatments
● Studying a novel blood biomarker as a tool for earlier detection
● Improving the safety and effectiveness of alpha-particle radioligand therapy
In this new group of grantees, NETRF is funding six Investigator Awards, two Pilot Awards and two Mentored Research Awards, all focusing on basic and translational science. Six of the 10 awardees are first-time grant recipients of NETRF. The grant recipients are selected through a competitive and rigorous scientific peer-review process.
Academic institutions receiving NETRF funding include The University of Texas MD Anderson
Cancer Center, The University of Texas Health Science Center at Houston, University of Iowa
Health Care, Laval University in Quebec, Massachusetts General Hospital, Korea Military
Academy, Dana-Farber Cancer Institute, Stanford University School of Medicine, and UCLA
More on EntSun News
David Geffen School of Medicine.
Since its founding in 2005, NETRF has provided funding for 156 research projects at 76
institutions in 17 countries worldwide.
"Our role of building and nurturing the neuroendocrine cancer research community is vital.
NETRF is often the sole source of funding for early-career scientists with groundbreaking
ideas," said Todd Gilman, president of NETRF's board of directors. "We're proud that the
innovative researchers we've funded are making important discoveries that will have positive
impacts on the patient community."
Gellerman thanked the many individuals and foundations whose financial gifts support NETRF's research and education programs, including generous funding from The Carol DeBacker Charitable Trust, the Martha O'Donnell Pagel Fund for Rare Cancer Research, Karpus Family Foundation, Jim Rodin, Laura and Lew Moorman, and Katherine's Light Foundation.
NETRF is the largest global funder of neuroendocrine cancer research and the preeminent resource for expert patient education and support. https://www.NETRF.org
understanding and treating neuroendocrine cancer. Funding for these ten grants totals $2
million, bringing NETRF's all-time investment in research to $39.8 million.
"As the largest global funder of neuroendocrine cancer research, NETRF is the lifeline for
dedicated scientists working tirelessly to unravel the complexities of this uncommon and
challenging disease," said Elyse Gellerman, NETRF's chief executive officer. "NETRF is making the impossible, possible by accelerating leading-edge research in early detection and
personalized treatments. With this crucial funding, we're not just advancing science—we're
paving the way to a future without neuroendocrine cancer," she said.
The new awardees will focus on these themes in neuroendocrine cancer research:
More on EntSun News
- North Texas Entrepreneur Jeanette Greenwood Launches "The Vision Cut" as Texas Film Industry Surges
- Williamsville Spa Expands Team to Meet Growing Demand for Professional Facials
- Pregis Expands Wind Energy Use, Advancing Progress Toward Net Zero by 2040
- Dr. Sheel Desai Solomon and Preston Dermatology Continue Awards Streak with Top Honors in 2026 Maggy Awards
- Jack and Sage Acquires Sustainable Apparel Brand Kastlfel, Expanding Premium Logo Wear Across National Parks and Ski Resorts
● Discovering the origins of neuroendocrine cancer and causes of disease progression
● Investigating new molecular targets for treatment
● Identifying novel approaches to combat drug resistance to existing treatments
● Studying a novel blood biomarker as a tool for earlier detection
● Improving the safety and effectiveness of alpha-particle radioligand therapy
In this new group of grantees, NETRF is funding six Investigator Awards, two Pilot Awards and two Mentored Research Awards, all focusing on basic and translational science. Six of the 10 awardees are first-time grant recipients of NETRF. The grant recipients are selected through a competitive and rigorous scientific peer-review process.
Academic institutions receiving NETRF funding include The University of Texas MD Anderson
Cancer Center, The University of Texas Health Science Center at Houston, University of Iowa
Health Care, Laval University in Quebec, Massachusetts General Hospital, Korea Military
Academy, Dana-Farber Cancer Institute, Stanford University School of Medicine, and UCLA
More on EntSun News
- Bay Street Yard to host Shaggy Tropical Block Party on March 10
- 7th Annual Waco Family & Faith International Film Festival Celebrates Music in Movies and Empowers The Community
- BeReal Wear Marks Mother's Day 2026 with Up to 50% Off
- The Projection Booth Celebrates 15 Years of Deep-Dive Film Conversation
- Beau Jest at North Coast Repertory Theatre
David Geffen School of Medicine.
Since its founding in 2005, NETRF has provided funding for 156 research projects at 76
institutions in 17 countries worldwide.
"Our role of building and nurturing the neuroendocrine cancer research community is vital.
NETRF is often the sole source of funding for early-career scientists with groundbreaking
ideas," said Todd Gilman, president of NETRF's board of directors. "We're proud that the
innovative researchers we've funded are making important discoveries that will have positive
impacts on the patient community."
Gellerman thanked the many individuals and foundations whose financial gifts support NETRF's research and education programs, including generous funding from The Carol DeBacker Charitable Trust, the Martha O'Donnell Pagel Fund for Rare Cancer Research, Karpus Family Foundation, Jim Rodin, Laura and Lew Moorman, and Katherine's Light Foundation.
NETRF is the largest global funder of neuroendocrine cancer research and the preeminent resource for expert patient education and support. https://www.NETRF.org
Source: Neuroendocrine Tumor Research Foundation
0 Comments
Latest on EntSun News
- Tarrytown Expocare Pharmacy Announces Strategic Leadership Appointments to Accelerate Growth and Innovation
- New Environmental Thriller "The Star Thrower" Reimagines a Classic Lesson in Individual Impact
- Summit Appoints Javier Cabeza as Data, AI, and Analytics Practice Lead
- NYC Celebrity Psychic Documents 6-Fight UFC & Boxing Prediction Streak
- March Is Skiing's Smartest Buying Window
- Cancun Airport Transportation Expands Fleet Ahead of Record Passenger Growth at Cancun International Airport
- Tobu Group's "T-home Series" of Accommodations in Tokyo Just Opened "T-home KEI."
- Seedance 2.0 & Kling 3.0: SeeVideo.dance Debuts Pro Web AI Video Workspace
- Mike Rowe Shares "Dirty Jobs" Stories and More on MASTERS by Winn Claybaugh Podcast and YouTube
- Custom Wooden Token Manufacturer Celebrates 10 Years of Helping Brands Stay Top of Mind
- NaturismRE Launches the NRE Health Institute to Advance Evidence-Informed Public Health Research
- P-Wave Classics to publish Robert Bage's Hermsprong in three volumes, beginning 12 May
- Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
- CCHR: While Damaging Antipsychotics Win Approval, Proven Non-Drug Alternatives Remain Ignored
- Arcuri Group Announces Long‑Term Partnership with WakeMed Health & Hospitals to Deliver Situational Awareness and De‑escalation Training
- Inside NobleCon 2025: Aiden McNally with Wealth Strategy Media Interviews Chairman Sean P. Jackson
- Ghostlight Ensemble Announces Cast For 'The Dover Road'
- At 25, She Became One of the Youngest AAPI Female Founders to Win One of the World's Most Prestigious Design Awards for a Lamp That Makes You Smile
- Juego Studios Extends Full-Cycle Game Development & Outsourcing Capabilities to the UAE Market
- iPOP Alum Elizabeth Zacero competing in Survivor Croatia